Revolution Medicines (NASDAQ:RVMD) Shares Break Below 200 Day Moving Average on Insider Selling

Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report)’s stock price passed below its 200-day moving average during trading on Wednesday after an insider sold shares in the company. The stock has a 200-day moving average of $160.40 and traded as low as $158.34. Revolution Medicines shares last traded at $159.82, with a volume of 2,339,794 shares changing hands.

Specifically, insider Stephen Kelsey sold 27,160 shares of Revolution Medicines stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $167.86, for a total value of $4,559,077.60. Following the transaction, the insider directly owned 286,307 shares of the company’s stock, valued at $48,059,493.02. This trade represents a 8.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Jack Anders sold 35,750 shares of the business’s stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $188.10, for a total transaction of $6,724,575.00. Following the transaction, the chief financial officer owned 119,216 shares of the company’s stock, valued at approximately $22,424,529.60. This represents a 23.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Wolfe Research restated an “outperform” rating and set a $220.00 target price on shares of Revolution Medicines in a research note on Monday, August 10th. Piper Sandler lifted their price target on Revolution Medicines from $210.00 to $222.00 and gave the company an “overweight” rating in a research note on Thursday, November 5th. Wall Street Zen raised Revolution Medicines from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Royal Bank Of Canada upped their price objective on Revolution Medicines from $260.00 to $321.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. Finally, Brookline Capital Markets started coverage on Revolution Medicines in a research report on Monday, September 28th. They set a “buy” rating and a $318.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Revolution Medicines presently has an average rating of “Moderate Buy” and a consensus target price of $262.75.

Check Out Our Latest Report on Revolution Medicines

Revolution Medicines Price Performance

The stock has a fifty day moving average of $190.87 and a two-hundred day moving average of $160.71. The company has a quick ratio of 8.34, a current ratio of 8.36 and a debt-to-equity ratio of 0.44.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($1.90) EPS for the quarter, topping analysts’ consensus estimates of ($2.35) by $0.45. The company had revenue of $197.56 million during the quarter, compared to analyst estimates of $25.58 million. During the same period in the prior year, the firm earned ($1.61) earnings per share. On average, sell-side analysts anticipate that Revolution Medicines, Inc. will post -7.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Alphabet Inc. acquired a new position in shares of Revolution Medicines during the 2nd quarter valued at $551,843,000. Assenagon Asset Management S.A. lifted its position in Revolution Medicines by 987.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company’s stock valued at $447,710,000 after acquiring an additional 1,980,699 shares in the last quarter. Winslow Capital Management LLC purchased a new position in shares of Revolution Medicines during the third quarter valued at approximately $260,191,000. Bank of America Corp DE purchased a new position in Revolution Medicines during the 2nd quarter worth $184,267,000. Finally, Deutsche Bank AG bought a new stake in Revolution Medicines in the 2nd quarter worth about $166,308,000. 94.34% of the stock is owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

(Get Free Report)

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.

Recommended Stories

Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.